PRSS contributes to cetuximab resistance in colorectal cancer | Science Advances
Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study - European Journal of Cancer
Cetuximab (Erbitux) - an EGF inhibitor for Colorectal cancer
Cetuximab | SpringerLink
![Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study [PeerJ]](https://dfzljdn9uc3pi.cloudfront.net/2020/9862/1/fig-1-full.png "Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study [PeerJ]")
Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study [PeerJ]
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck | NEJM
ERBITUX (cetuximab) for Head and Neck Cancer and Colorectal Cancer - Cancer Therapy Advisor
JCI Insight - First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members | Oncogene
The challenge of managing a cetuximab rash | MDedge Hematology and Oncology
PPT - Management of Metastatic Colorectal Cancer: Focus on Targeted Therapy PowerPoint Presentation - ID:437568
REACH treatment schedule: Cetuximab (Erbitux®) is given at a loading... | Download Scientific Diagram
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study - Annals of Oncology
Dose-response curves of cetuximab in NPC cell lines. Cells were... | Download Scientific Diagram
Regimen Reference Order – H&N – cetuximab + fluorouracil + CARBOplatin
Locoregional Head & Neck Cancer | HCP | ERBITUX (cetuximab)
Frontiers | Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60
Addition of cetuximab to chemotherapy shortens OS in advanced colorectal cancer subset
Cancers | Free Full-Text | Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G | HTML
Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience - International Journal of Radiation Oncology, Biology, Physics
Cetuximab in the management of nasopharyngeal carcinoma – a narrative review | The Journal of Laryngology & Otology | Cambridge Core
cetuximab
